Doctor’s Guide -- MONTREAL -- October 27, 2010 -- There is no statistically significant increase in the risk of major bleeding in patients who receive triple antithrombotic therapy (aspirin, thienopyridine, and vitamin K antagonist) versus dual antiplatelet therapy (DAT) after undergoing primary percutaneous coronary intervention (PCI), researchers said here at the 2010 Canadian Cardiovascular Congress (CCC).
